Comparison of haemodynamic responses to dopamine and salbutamol in severe cardiogenic shock complicating acute myocardial infarction

A D TIMMIS, M B FOWLER, D A CHAMBERLAIN

Abstract

Twelve patients with severe persistent cardiogenic shock complicating acute myocardial infarction underwent single crossover treatment with intravenous dopamine and salbutamol to determine the more beneficial therapy. Salbutamol (10 to 40 µg/min) reduced systemic vascular resistance and progressively increased both cardiac index and stroke index. Heart rate increased from 95 to 104 beats/min. Changes in mean arterial pressure and pulmonary artery end-diastolic pressure were small and insignificant. Dopamine infusion at rates of 200 and 400 µg/min also increased cardiac index and stroke index. Systemic vascular resistance fell slightly but mean arterial pressure rose from 57 to 65 mm Hg. Heart rate increased from 95 to 105 beats/min. Changes in pulmonary artery end-diastolic pressure were again small and insignificant. Dopamine infusion at 800 µg/min caused an appreciable increase in systemic vascular resistance; a further increment in mean arterial pressure was observed, though cardiac index fell slightly. Heart rate and pulmonary artery end-diastolic pressure rose steeply.

Salbutamol, a vasodilator, increased cardiac output in patients with cardiogenic shock complicating acute myocardial infarction but did not influence blood pressure. If correction of hypotension is essential dopamine in low doses may be the preferred agent. Doses of 800 µg/min, which is within the therapeutic range, worsen other manifestations of left ventricular dysfunction.

Introduction

Dopamine, a precursor in the endogenous synthesis of noradrenaline is widely used in the treatment of cardiogenic shock complicating acute myocardial infarction1-2; blood pressure and cardiac output may both be increased by its agonist activity at α- and β-adrenoceptors. Recent reports have shown that salbutamol, a relatively specific β₂-adrenoceptor agonist with vasodilator properties, also has beneficial haemodynamic effects in this condition.4 7

Cardiogenic shock carries a mortality close to 100% when initially refractory or unusually severe. The prompt administration of a drug providing the most suitable haemodynamic support may make a small impact on prognosis and on the quality of life of those who do survive. Unfortunately, few drug comparisons have been made in this condition. Moreover, recommendations for treatment are often based on effects elicited in patients who do not have myocardial damage of an extent that critically limits haemodynamic response. In attempting to provide the most effective treatment for patients with severe cardiogenic shock after myocardial infarction, we compared haemodynamic responses to salbutamol and dopamine since this information has not been available as a guide to management.

Patients and methods

The haemodynamic effects of dopamine and salbutamol were compared in patients with critical cardiogenic shock who had not responded adequately, or who seemed unlikely to respond, to our conventional treatment, including vasodilators. We used a single crossover design, with the intention of alternating the order in which the drugs were given.

Difficulties arose with the order of drug administration because the patients studied did not constitute a consecutive series of those admitted with shock. Thus several patients were treated electively with salbutamol and one electively with dopamine. Another, whose condition improved considerably with salbutamol, was withdrawn from the study, since a change in treatment at that stage was not considered ethical. Four patients who were considered for the trial died before comparative observations had been made.
Of the patients remaining in the study, seven received dopamine before salbutamol and five received salbutamol first. Their ages ranged from 49 to 78 years (mean 67). All had electrocardiographic evidence of acute myocardial infarction (eight anterior and four inferior). One patient was in atrial fibrillation, another was paced at a rate of 100 beats/min, and the remainder were in sinus rhythm. The patients had severe cardiogenic shock with cold clammy skin, systolic blood pressure below 90 mm Hg, and a urine output of less than 20 ml/hour which had not increased with intravenous diuretics. No other inotropic or vasodilator drugs were given during the study, although all the patients were well sedated with opiates and eight had been given digitalis.

Observations were made in the coronary care unit within 36 hours of admission. Radial artery and right heart pressures and cardiac output were measured as previously described.4

Dopamine and salbutamol were each diluted in 5% dextrose and administered by an infusion pump (Watson Marlow Ltd) into a central vein. Dopamine was infused at 200 then 400 and finally 800 μg/min. Salbutamol was infused at 10 then 20 and finally 40 μg/min. Infusion rates were increased every 20 minutes and haemodynamic measurements were made before each dose increment. After the maximal dose increment of each drug the infusion were discontinued and further haemodynamic measurements made 30 minutes later. At the end of the study the patients were treated with the agent which had produced the more favourable haemodynamic response.

Discussion

Cardiogenic shock in acute myocardial infarction occurs when at least 45% of the left ventricle has been damaged.6 The most important haemodynamic consequence is a critical reduction in cardiac output with systemic hypotension and impaired perfusion of vital organs. Left ventricular filling pressure is also often considerably raised, resulting in pulmonary oedema. Treatment is aimed at correcting these haemodynamic indices without incurring an unacceptable metabolic cost to the ischaemic myocardium.

Dopamine is an adrenergic agonist. Stimulation of cardiac β-receptors7 and arteriolar α-receptors8 accounts, respectively, for its inotropic and pressor activity. It also causes direct dilatation of the renal and mesenteric vascular beds.9,10 Salbutamol too is an adrenergic agonist but has β2-specificity11 and thereby induces peripheral arteriolar dilatation with little direct cardiotropic activity. This allows cardiac output to increase by reducing left ventricular afterload.

Results

The haemodynamic effects of dopamine and salbutamol infusions are summarised in the table, and dose response curves are shown in the figure. Salbutamol caused a progressive dose-related increase in cardiac index and stroke index. Heart rate increased by only 9 beats/min at the maximum dose increment. Blood pressure was not appreciably altered despite a progressive reduction in systemic vascular resistance. Changes in pulmonary artery end-diastolic pressure were small and not statistically significant.

Dopamine infusion at the first and second dose increments (200 and 400 μg/min) also caused dose-related increments in cardiac index and stroke index. Heart rate increased by only 10 beats/min. Mean blood pressure increased by 8 mm Hg despite a small reduction in systemic vascular resistance. Changes in pulmonary artery end-diastolic pressure were small and not statistically significant.

With the infusion of dopamine at 800 μg/min a small fall in cardiac index was observed. Moreover, the heart rate increased considerably, resulting in a sharp decline in stroke index. Blood pressure continued to rise as a result of increased systemic vascular resistance. Pulmonary artery end-diastolic pressure rose steeply.

The mean value for stroke work index before treatment was only 10 g m⁻¹ m⁻¹ (range 5-15 g m⁻¹). Despite useful increments in this variable with both dopamine and salbutamol the median survival was only five days (range 1 to 14 days), and no patient survived to leave hospital.

### Haemodynamic effects of salbutamol and dopamine in cardiogenic shock in 12 patients. Values are means ±SEM

<table>
<thead>
<tr>
<th>Control</th>
<th>1st increment</th>
<th>2nd increment</th>
<th>3rd increment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Salbutamol</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac index (l/min/m²)</td>
<td>1.6±0.1</td>
<td>10 μg/min</td>
<td>20 μg/min</td>
</tr>
<tr>
<td>Mean systemic arterial pressure (mm Hg)</td>
<td>59±5</td>
<td>60±5</td>
<td>61±5</td>
</tr>
<tr>
<td>Right atrial pressure (mm Hg)</td>
<td>2±1</td>
<td>2±1</td>
<td>2±1</td>
</tr>
<tr>
<td>Pulmonary artery end-diastolic pressure (mm Hg)</td>
<td>18±1</td>
<td>18±1</td>
<td>18±1</td>
</tr>
<tr>
<td>Systemic vascular resistance (units)</td>
<td>53±3</td>
<td>55±2</td>
<td>54±2</td>
</tr>
<tr>
<td>Stroke volume index (ml/beat/m²)</td>
<td>17±2</td>
<td>18±2</td>
<td>20±2</td>
</tr>
<tr>
<td>Stroke work index (g m⁻¹ m⁻¹)</td>
<td>10±1</td>
<td>11±1</td>
<td>13±1</td>
</tr>
</tbody>
</table>

| **Dopamine** | | | |
| Cardiac index (l/min/m²) | 1.7±0.1 | 200 μg/min | 400 μg/min |
| Mean systemic arterial pressure (mm Hg) | 57±3 | 60±3 | 65±4 | 73±5* |
| Right atrial pressure (mm Hg) | 3±1 | 3±1 | 3±1 |
| Pulmonary artery end-diastolic pressure (mm Hg) | 18±2 | 19±2 | 22±2 | 25±2* |
| Systemic vascular resistance (units) | 19±2 | 19±2 | 20±2 | 20±2 |
| Stroke volume index (ml/beat/m²) | 18±1 | 20±1 | 21±1 |
| Stroke work index (g m⁻¹ m⁻¹) | 10±1 | 12±2 | 14±2 | 12±1 |

Reference point for pressures was sternal angle (add 5 mm Hg to equate with mid-chest readings).

*<0.05; †<0.02; ‡<0.01; §<0.001.
Our results confirm that in patients with cardiogenic shock salbutamol reduces systemic vascular resistance and improves cardiac output. The increase in cardiac output is sufficient to offset any tendency for blood pressure to fall in response to arteriolar dilatation.

The more complex actions of dopamine are reflected in our data, which show important differences in the type of response depending on the infusion rate. At all doses dopamine acted on the myocardium to increase heart rate and, by inference, contractility. The peripheral effects of dopamine, however, were almost opposite. The selective arteriolar dilatation was clearly dominant at low doses and was responsible for the small fall in vascular resistance at 200 μg/min. Thereafter its more gradual α-agonist (noradrenaline-like) action became more important, as reflected by the progressive rise in vascular resistance and blood pressure. Despite continuing inotropic drive, a damaged myocardium cannot respond adequately to the increased pressure load. Thus at the highest dose increment in our patients the indirect left atrial pressure rose steeply, tachycardia increased strikingly, and the rise in cardiac output was attenuated.

We have previously postulated that salbutamol, with its dominantly peripheral mode of action, increases cardiac output at little cost to the heart in terms of oxygen consumption. The effect of dopamine on heart rate and blood pressure with infusion at 800 μg/min indicates that this drug can increase myocardial oxygen requirements considerably. A recent study investigating the effects of dopamine on myocardial metabolism confirms that the drug is potentially harmful to the ischaemic myocardium.

These adverse haemodynamic and metabolic effects of dopamine are very similar to those observed by Lett et al. in patients with congestive cardiomyopathy. To some extent the ill effects may be mitigated by simultaneously infusing vasodilators such as nitroprusside, which reduce myocardial oxygen demand and further increase cardiac output by their action on left ventricular afterload. Salbutamol and nitroprusside also have useful additive effects in severe left ventricular failure and some of our patients were continued on such combination regimens when optimum doses of dopamine and salbutamol had been selected.

We did not formally measure the effects of these agents on urine output since routine bladder catheterisation in cardiogenic shock was not then our practice. Previous work has shown that dopamine selectively increases renal blood flow and will often induce a diuresis in patients with oliguric heart failure. Salbutamol reliably increases cardiac output in such patients but we do not know whether renal perfusion is improved; dilatation of cutaneous and muscular vascular beds might divert flow away from vital organs. We have been impressed, however, by the urinary response of our patients to salbutamol, implying that this drug—like dopamine—improves renal perfusion.

This group of patients constituted a selected series with severe cardiogenic shock as reflected by a mean stroke work index before treatment of only 10 g m⁻². Mortality approaches 100% in such patients and the uniformly unfavourable outcome in our patients was therefore disappointing but not surprising.

The data we obtained may not reflect responses in those with less severe myocardial damage. In particular, patients with smaller infarcts would be capable of greater increments in cardiac output and may have tolerated more readily the rise in blood pressure caused by the peripheral actions of dopamine. If drugs are to be used successfully for cardiogenic shock we believe that patients should be treated promptly before shock becomes irreversible. Drug selection should depend on the pattern of the haemodynamic derangement in individual patients.

Our findings show that both dopamine and salbutamol increase cardiac output in patients with cardiogenic shock complicating acute myocardial infarction. Neither drug reduces left atrial pressure unless venodilators are used concurrently. If correction of low output is the primary aim salbutamol may be preferred to dopamine since it is likely to be more sparing in its demands on myocardial oxygen consumption. Salbutamol, however, does not influence blood pressure, and when correction of hypotension is of overriding importance dopamine is more useful. Caution is necessary, however, since larger doses of dopamine (800 μg/min) worsen other manifestations of left ventricular dysfunction.

We thank Glaxo Group Research Limited and American Critical Care (UK) Limited (Arnar Stone) for financial support.

References

(Accepted 23 October 1980)

ONE HUNDRED YEARS AGO Last week the London Temperance Hospital was formally opened by the Lord Mayor. According to the statement read, the hospital was first opened at 112, Gower Street, in 1879, and had since relieved 954 in-patients and 8,006 out-patients. It was established to give a scientific trial to the non-alcoholic treatment of disease; and although provision was made for the use of alcohol should the medical staff deem it necessary in any special case, yet in point of fact, this provision had been acted upon but once, and that without benefit to the patient herself. Many severe cases, both medical and surgical, had been treated on the non-alcoholic system with marked success, and the Board had thus been encouraged to provide the larger field of hospital practice inaugurated that day. (British Medical Journal, 1881.)